Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03474965
Recruitment Status : Suspended (Novartis has temporarily halted the recruitment of new patients until the dose in Group 2 is confirmed. The safety and benefit/risk remain unchanged and enrolled patients continue to be treated as per protocol.)
First Posted : March 23, 2018
Last Update Posted : December 17, 2021
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : June 5, 2023
Estimated Study Completion Date : November 20, 2024